All Pharmaceutical Microbiology articles – Page 4
-
NewsScientists fight drug-resistant parasites with nature-inspired drugs
As parasites become increasingly resistant to existing drugs, researchers are working to develop a new generation of treatments for two serious infectious diseases: malaria and babesiosis.
-
NewsTwo deadly flowers have big medical potential
Two plants that cause neurotoxicity and paralysis in the tiniest doses are also known to counter pain, malaria, cancer and pests. For the first time, researchers have discovered a way to recreate these powerful compounds in the lab - with the help of yeast.
-
NewsTuberculosis drug discovery gets smarter with AI
Scientists have built an artificial intelligence tool to help scientists focus their efforts after initial screening of potential tuberculosis drugs. The team is also using AI to organize years of collaborative data into a searchable form.
-
NewsNew antimicrobials could help tackle deadly drug-resistant infections
Scientists have developed a promising new way to create safer and more effective treatments for life-threatening fungal infections. Using genome mining, they identified bacterial species capable of producing new, undiscovered antifungals.
-
NewsRemdesivir for COVID-19 linked to better outcomes for adult kidney transplant recipients
Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of diagnosis were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascular or kidney problems up to a year later.
-
NewsBeyond antibiotics—a paradigm shift toward bacteria-control-centric therapies
A novel extracellular vesicle platform helps polymyxins kill multidrug-resistant gram-negative bacteria at lower and potentially safer doses.
-
News A secret weapon against superbugs
A molecular library of potential adjuvants has been used to help restore the activity of vancomycin, a powerful antibiotic widely used to treat serious infections such as MRSA and Clostridium difficile (C. diff).
-
NewsResearchers find a new way to tackle drug-resistant infections - starvation
A drug designed to block ECF transporters would attack the bacteria while leaving human cells largely unaffected, substantially reducing the risk of side effects. A research team has succeeded in developing exactly such a drug candidate.
-
NewsLast-line antibiotics at risk as children’s resistance rises
Antimicrobial resistance in children is rising globally and will worsen over the next decade, threatening the effectiveness of life‑saving antibiotics, according to a world-first monitoring platform.
-
NewsExpanding uses for bioengineered bacterial spores
Fused to the outer layer of bacterial spores, things like enzymes, biosensors, and drugs are easily stored under even extreme conditions.
-
NewsNovel antifungal drug shows promise in some patients with Valley Fever
A study found that olorofim, a first-in-class orotomide antifungal agent, showed efficacy in patients with disseminated coccidioidomycosis (DCM), a rare complication of Valley Fever where the fungus spreads from the lungs to other parts of the body.
-
NewsROS–Jak2/Stat3 signaling drives HBV-induced liver inflammation
Scientists investigated the mechanisms underlying HBV-induced liver inflammation and identified a reactive oxygen species (ROS)-dependent signaling cascade that activates the Jak2/Stat3 pathway, thereby triggering hepatic inflammatory responses.
-
NewsGenetically engineered Bifidobacterium shows potential for oral delivery of cancer vaccines
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. In an exploratory phase I clinical study, the vaccine was well tolerated and generated immunologic and clinical findings that warrant further investigation.
-
NewsFirst clinical proof of concept for ibuprofen as an adjunctive treatment for tuberculosis
Scientists have published the results of a phase IIa pilot clinical trial assessing ibuprofen as a host-directed therapy in patients with pre-extensively drug-resistant tuberculosis (pre-XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).
-
NewsNew project ORIGIN aims to redefine how society accesses natural ingredients
The ORIGIN consortium will develop an integrated AI-supported platform designed to accelerate the path from natural molecules to sustainable, fermentation-based ingredients. The project aims to reduce development timelines to two to three years.
-
NewsBrazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment
Following a licensing agreement signed between the Serum Institute of India (SII) and DNDi, a Phase III clinical trial is expected to begin early next year, with the aim of developing a safe, effective, and globally accessible therapeutic for dengue.
-
NewsResearchers identify a marine bacterial enzyme that opens a new route to build bioactive compound libraries
A research team has provided new insight into HapC, an enzyme from the marine bacterium Hahella chejuensis. They used modified short-chain versions of one key chemical building block and examined whether HapC could join them with another precursor to form new prodiginine compounds.
-
NewsGene-editing tool can unearth new cancer treatments from fungi
Engineers have developed a gene-editing tool built specifically for fungi, unlocking a hidden library of molecules—including some with early anti-cancer promise—from one of biology’s most overlooked kingdoms.
-
NewsCommon COVID-19 drugs may pose hidden risks to marine life, study finds
A new study suggests that several drugs widely used during the COVID-19 pandemic can be toxic to marine organisms, even at relatively low concentrations. Five pharmaceuticals were tested on nauplii of the brine shrimp Artemia salina.
-
NewsThe case for fewer antibiotics in joint replacement surgery
Infections are a leading cause of joint replacement failures, however a new study suggests prescription of an extended courses of antibiotics after patients leave the hospital may not be needed.